Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Index	-	P/Due east	-	EPS (ttm)	-1.15	Insider Own	0.40%	Shs Outstand	36.08M	Perf Week	-xiii.00%
Market place Cap	174.97M	Forrard P/E	-	EPS adjacent Y	-1.62	Insider Trans	0.00%	Shs Float	36.02M	Perf Calendar month	0.77%
Income	-41.20M	PEG	-	EPS next Q	-0.49	Inst Ain	93.40%	Short Float	iv.99%	Perf Quarter	39.57%
Sales	30.90M	P/Southward	5.66	EPS this Y	4.seventy%	Inst Trans	-0.06%	Short Ratio	seven.44	Perf Half Y	-44.88%
Book/sh	5.35	P/B	0.98	EPS next Y	ten.00%	ROA	-16.20%	Target Price	24.33	Perf Twelvemonth	-52.67%
Greenbacks/sh	half dozen.34	P/C	0.82	EPS adjacent 5Y	-	ROE	-20.10%	52W Range	2.83 - 17.50	Perf YTD	-58.37%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-16.twoscore%	52W High	-lxx.17%	Beta	-
Dividend %	-	Quick Ratio	eight.50	Sales by 5Y	-	Gross Margin	-	52W Low	84.45%	ATR	0.41
Employees	67	Current Ratio	8.l	Sales Q/Q	-ii.90%	Oper. Margin	-	RSI (14)	51.86	Volatility	7.99% 7.47%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-72.20%	Turn a profit Margin	-	Rel Volume	0.xiii	Prev Close	5.26
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	241.78K	Toll	v.22
Recom	1.threescore	SMA20	-0.72%	SMA50	11.45%	SMA200	-36.46%	Volume	32,124	Change	-0.76%

Dec-23-21 Initiated H.C. Wainwright Purchase $25 May-05-21 Resumed Credit Suisse Outperform $30 Apr-26-21 Resumed Credit Suisse Outperform $30 April-20-21 Initiated William Blair Outperform Apr-xx-21 Initiated Jefferies Buy Apr-20-21 Initiated Credit Suisse Outperform $30

Aug-12-22 07:41AM Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers Simply Wall St. Aug-11-22 08:45AM Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates Zacks 07:30AM Ikena Oncology Reports Second Quarter 2022 Fiscal Results and Provides a Corporate Update GlobeNewswire Jul-14-22 10:43AM How Much Of Ikena Oncology, Inc. (NASDAQ:IKNA) Exercise Institutions Own? Just Wall St. Jul-06-22 07:00AM Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 GlobeNewswire +six.38% Jun-22-22 07:00AM Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma GlobeNewswire +5.48% Jun-14-22 09:13AM We Think Ikena Oncology (NASDAQ:IKNA) Tin can Afford To Drive Business organisation Growth Simply Wall St. May-18-22 07:00AM Ikena Oncology to Participate in Leap 2022 Investor Conferences GlobeNewswire -7.23% May-15-22 08:41AM Ikena Oncology, Inc. (NASDAQ:IKNA) Just Reported Earnings, And Analysts Cutting Their Target Price Simply Wall St. May-13-22 08:28AM The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Commodities Biotherapeutics, Ikena Oncology, and Landos Biopharma Zacks May-12-22 08:35AM Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates Zacks 07:00AM Ikena Oncology Reports Showtime Quarter 2022 Financial Results and Provides a Corporate Update GlobeNewswire May-xi-22 08:44AM Is a Surprise Coming for Ikena Oncology (IKNA) This Earnings Season? Zacks -16.00% 07:32AM 5 Biotech Stocks Prepare to Outpace Q1 Earnings Estimates Zacks May-02-22 07:00AM Ikena Oncology and Vall dHebron Plant of Oncology Announce Enquiry & Evolution Collaboration GlobeNewswire April-28-22 07:00AM Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Coming together GlobeNewswire -x.49% Apr-xiii-22 07:00AM Ikena Appoints Jotin Marango, G.D., Ph.D., as Chief Fiscal Officeholder and Head of Corporate Development GlobeNewswire +seven.35% April-12-22 02:01PM 10 Best Micro-Cap Stocks to Buy According to Hedge Funds Insider Monkey Mar-28-22 05:37PM Ikena Oncology (NASDAQ:IKNA shareholders incur farther losses as stock declines 16% this week, taking i-yr losses to 79% Simply Wall St. Mar-17-22 07:00AM Ikena Oncology Reports Fourth Quarter and Full Year 2021 Fiscal Results and Corporate Update GlobeNewswire +23.thirty% Mar-07-22 04:30PM Ikena Oncology to Nowadays Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Almanac Meeting GlobeNewswire Mar-01-22 07:00AM Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference GlobeNewswire Feb-03-22 04:35PM Summit 10 Stock Picks of Samuel Isalys OrbiMed Advisors Insider Monkey -xiv.76% Jan-26-22 07:00AM Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors GlobeNewswire Dec-24-21 12:38AM Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com Dec-23-21 06:05AM Here's Why We're Non As well Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Situation Just Wall St. Dec-18-21 12:38AM Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com December-17-21 08:00AM Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies PR Newswire -v.61% Dec-08-21 07:00AM Ikena Appoints Michelle Zhang, Ph.D., Manufacture and Visitor Veteran, equally Chief Scientific Officeholder GlobeNewswire +13.73% November-12-21 07:00AM Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Information, and Trial in Progress for IK-175 GlobeNewswire Nov-10-21 07:00AM Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update GlobeNewswire +x.94% November-04-21 07:00AM Ikena Oncology to Participate in November 2021 Virtual Investor Conferences GlobeNewswire Nov-02-21 08:00AM Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930 GlobeNewswire +8.93% Oct-07-21 09:00AM Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment GlobeNewswire +9.21% Oct-01-21 08:15AM Ikena Oncology to Present a Trial-in-Progress Update, Translational Information, and Indication Choice Methodology for Novel AHR Inhibition Program at the 2021 Lodge for Immunotherapy of Cancer (SITC) 36th Annual Meeting GlobeNewswire Sep-02-21 07:00AM Ikena Oncology to Participate in September 2021 Virtual Investor Conferences GlobeNewswire Aug-12-21 07:00AM Ikena Oncology Reports 2d Quarter 2021 Fiscal Results and Provides Update on Key Programs GlobeNewswire +7.fifty% Jul-08-21 07:00AM Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021 GlobeNewswire Jun-26-21 05:18AM Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth Simply Wall St. May-26-21 07:00AM Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Briefing Business Wire May-13-21 07:00AM Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021 Business Wire -13.61% Apr-15-21 07:00AM Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors Business Wire Mar-30-21 04:05PM Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Pick to Buy Additional Shares Business Wire -9.54% Mar-25-21 08:55PM Ikena Oncology Announces Pricing of Initial Public Offer Business concern Wire

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its pb targeted oncology production candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. Information technology is likewise developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the handling of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Insider Trading Human relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4 Tessier Maude Chief Business Officeholder January 18 Choice Practice three.54 71,786 253,800 100,578 Jan xx 04:30 PM Zhang Xiaoyan Michelle Chief Scientific Officer Jan xi Pick Exercise 2.15 964 2,069 45,439 Jan 12 07:25 PM Zhang Xiaoyan Michelle Chief Scientific Officeholder Jan 11 Sale 12.00 964 xi,568 44,475 Jan 12 07:25 PM Zhang Xiaoyan Michelle Chief Scientific Officer Jan 10 Option Exercise 2.fifteen 36 77 44,511 Jan 12 07:25 PM Zhang Xiaoyan Michelle Principal Scientific Officer Jan ten Sale 12.00 36 432 44,475 Jan 12 07:25 PM FORMELA JEAN FRANCOIS Managing director Dec xiv Sale 14.00 5,959 83,426 1,241,935 December 14 08:29 PM Atlas Venture Fund Eleven, L.P. ten% Possessor Dec 14 Sale 14.00 5,959 83,426 1,241,935 Dec 14 08:27 PM Atlas Venture Fund XI, L.P. ten% Owner December thirteen Auction 14.64 8,330 121,951 ane,247,894 Dec fourteen 08:27 PM FORMELA JEAN FRANCOIS Director Dec xiii Auction 14.64 8,330 121,951 1,247,894 December 14 08:29 PM Zhang Xiaoyan Michelle Master Scientific Officer Dec 10 Pick Exercise 2.xv 1,000 2,146 45,475 December 14 08:48 PM Zhang Xiaoyan Michelle Principal Scientific Officer Dec ten Sale fourteen.76 one,000 14,760 44,475 Dec 14 08:48 PM FORMELA JEAN FRANCOIS Director Dec 10 Sale 15.03 eleven,989 180,195 1,256,224 December xiv 08:29 PM Atlas Venture Fund Xi, L.P. 10% Owner December 10 Auction 15.03 11,989 180,195 1,256,224 December 14 08:27 PM

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more most FINVIZ*Aristocracy

Source: https://finviz.com/quote.ashx?t=IKNA

Posted by: jacobsfure1940.blogspot.com

Share this post